What disease mechanisms contribute to multisystem tissue involvement in dominant optic atrophy due to OPA1 mutations?
What disease mechanisms contribute to multisystem tissue involvement in dominant optic atrophy due to OPA1 mutations?
批准号:
G1002570/1
负责人:
Patrick Yu Wai Man
金额:
$114.44万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2012
资助国家:
英国
项目状态:
已结题
起止时间:
2012 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Autosomal dominant optic atrophy (DOA) affects the optic nerve, causing insidious visual loss from early childhood. It is the most common inherited optic nerve disorder and the majority of patients carry mutations in OPA1, a nuclear gene critical for normal mitochondrial function. Mitochondria are essential components of all human cells, containing multiple copies of their own DNA (MtDNA), and forming long branching networks which fuel the cell‘s energy requirements.About 20% of patients with OPA1 mutations will develop a more severe form of the disease (DOA+), associated with a worse visual prognosis and additional neurological complications. The risk of developing DOA+ is three times higher with missense mutations located within the GTPase gene region. Using a range of human tissue samples, I will investigate whether this specific mutational subgroup results in greater fragmentation of the mitochondrial network and more marked mtDNA damage, thus contributing to accelerated cell death. I will also explore the possibility of rescuing the fragmentation defect by manipulating the level of expression of OPA1 and other mitochondrial proteins involved in network fusion and fission. Visual loss in DOA is progressive and the neurological features develop in later life, providing a clear window of opportunity for therapeutic intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Do secondary mitochondrial DNA defects cause retinal ganglion cell death in dominant optic atrophy?
-
批准号:G0701386/1
-
项目类别:Fellowship
-
资助金额:$25.14万
-
财政年份:2008
-
负责人:Patrick Yu Wai Man
-
依托单位:
国内基金
海外基金
登录
查看更多内容
黏液层/细菌被膜双重渗透型抗菌聚多肽纳米载体用于肺部给药治疗慢性阻塞性肺病
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:虞桂平
-
依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
-
批准号:82371801
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:周海波
-
依托单位:
Erk1/2/CREB/BDNF通路在CSF1R相关性白质脑病致病机制中的作用研究
-
批准号:82371255
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:曹立
-
依托单位:
肠道菌群介导的脱氧胆酸激活S1PR2/NLRP3/IL-1β通路在炎症性肠病合并艰难梭菌感染中的致病机制研究
-
批准号:82372306
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:彭奕冰
-
依托单位:
噬菌体靶向肠道粪肠球菌提高帕金森病左旋多巴疗效的机制研究
-
批准号:82371251
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:肖勤
-
依托单位:
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
-
批准号:82372073
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张淼
-
依托单位:
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
-
批准号:82370865
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄哲
-
依托单位:
牙周炎对腹主动脉瘤的作用和机制研究
-
批准号:82370953
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:朱亚琴
-
依托单位:
DJ-1与Calnexin互作调控线粒体—内质网联络区参与帕金森病病理机制的研究
-
批准号:82371414
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄沛
-
依托单位:
DACH1对糖尿病肾病足细胞脂质代谢的调控作用和机制研究
-
批准号:82370719
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:曹爱丽
-
依托单位: